Satoshi Akagi

Medicine & Life Sciences

1. (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid 7%
2. 1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol 22%
3. 6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol 7%
4. Amyloidosis, Hereditary, Transthyretin-Related 6%
5. Aneurysm 7%
6. Arteriovenous Malformations 6%
7. Atrial Heart Septal Defects 10%
8. beraprost 7%
9. Bosentan 7%
10. Cardiac Catheterization 7%
11. Cardiac Myocytes 10%
12. Cardiomegaly 13%
13. Catheter-Related Infections 6%
14. Diabetes Mellitus 6%
15. Drug Delivery Systems 8%
16. Elasticity 8%
17. Epoprostenol 54%
18. Familial Primary Pulmonary Hypertension 37%
19. Fibrosis 9%
20. Heart Failure 19%
21. Hemodynamics 12%
22. Hypertension 7%
23. Imatinib Mesylate 10%
24. Isoproterenol 6%
25. LCZ 696 12%
26. Lung 25%
27. Lung Transplantation 15%
28. Monocrotaline 24%
29. Myocarditis 8%
30. Nanoparticles 13%
31. Pharmaceutical Preparations 8%
32. Phosphodiesterase 5 Inhibitors 7%
33. Platelet-Derived Growth Factor 8%
34. Pressure 7%
35. Pulmonary Arterial Hypertension 100%
36. Pulmonary Arteriovenous Fistulas 6%
37. Pulmonary Artery 42%
38. Pulmonary Hypertension 34%
39. Pulmonary Veno-Occlusive Disease 7%
40. Receptor for Advanced Glycation End Products 10%
41. riociguat 6%
42. Sildenafil Citrate 6%
43. Smooth Muscle Myocytes 22%
44. Technetium Tc 99m Pyrophosphate 6%
45. Therapeutics 12%
46. Tomography 6%
47. Vascular Resistance 11%
48. Ventricular Heart Septal Defects 8%
49. Vildagliptin 5%
50. voglibose 15%